Mammalian heparanase (endo-b-glucuronidase) degrades heparan sulfate proteoglycans and is an important modulator of the extracellular matrix and associated factors. The enzyme is preferentially expressed in neoplastic tissues and contributes to tumour metastasis and angiogenesis. To investigate the epigenetic regulation of the heparanase locus, methylation-specific and bisulfite PCR were performed on a panel of 22 human cancer cell lines. Cytosine methylation of the heparanase promoter was associated with inactivation of the affected allele. Despite lack of sequence homology, extensively methylated CpG islands were found both in human choriocarcinoma (JAR) and rat glioma (C-6) cells which lack heparanase activity. Treatment of these cells with demethylating agents (5-azacytidine, 5-aza-2 0 -deoxycytidine) resulted in stable dose-and time-dependant promoter hypomethylation accompanied by reappearance of heparanase mRNA, protein and enzymatic activity. An inhibitor of histone deacetylase, Trichostatin A, failed to induce either of these effects. Upregulation of heparanase expression and activity by demethylating drugs was associated with a marked increase in lung colonization by pretreated C-6 rat glioma cells. The increased metastatic potential in vivo was inhibited in mice treated with laminaran sulfate, a potent inhibitor of heparanase activity. We propose a model wherein expression of mammalian heparanase gene is modulated by the interplay between trans-activating genetic and cis-inhibitory epigenetic elements in its promoter.
Introduction
Cancer metastases and angiogenesis depend, among other parameters, on the ability of cells (tumour cells, vascular endothelial cells) to invade basement membranes and tissue barriers in a process involving enzymes capable of degrading extracellular matrix (ECM) components (Liotta and Kohn, 2001 ). While the majority of studies focus on proteolytic enzymes and their inhibitors (Liotta and Kohn, 2001; Stetler-Stevenson and Yu, 2001) , the involvement of glycosaminoglycan (e.g., heparan sulfate (HS)) degrading enzymes (e.g., heparanase) was underestimated, primarily due to lack of appropriate molecular probes to explore their role in tumour progression. Research on the heparanase enzyme led to cloning of the corresponding human gene (Hulett et al., 1999; Toyoshima and Nakajima, 1999; Vlodavsky et al., 1999 ) that appears to play important roles in tumour metastasis, angiogenesis and tissue morphogenesis (Parish et al., 2001; Vlodavsky and Friedmann, 2001 ). Remarkably, a single dominant form of functional heparanase (HPSE) was found in mammalian cells, rendering the gene an indispensable element for important normal and pathological processes (Parish et al., 2001; Vlodavsky and Friedmann, 2001) . Indeed, overexpression of the enzyme in lowmetastatic tumour cells confers a highly invasive phenotype in experimental animals Goldshmidt et al., 2002) , while heparanaseinhibiting compounds reduce this effect (Nakajima et al., 1988; Miao et al., 1999) . Elevated levels of heparanase expression correlate with increased tumour vascularization (Gohji et al., 2001 ) and shorter postoperative survival of cancer patients (Gohji et al., 2001; Koliopanos et al., 2001) .
Heparan sulfate proteoglycans (HSPGs) are ubiquitous macromolecules associated with the ECM and surface of a wide range of cells (Iozzo, 1998; Bernfield et al., 1999; Esko and Lindahl, 2001) . The ability of HSPG to interact with various ECM macromolecules and with different attachment sites on plasma membranes suggests a key role for this proteoglycan in the self-assembly and insolubility of ECM components, as well as in cell adhesion and locomotion (Wight et al., 1992; Iozzo, 1998; Bernfield et al., 1999) . Cleavage of HS therefore plays a significant role in extravasation and dissemination of normal and malignant blood-borne cells (Vlodavsky et al., 1992; Vlodavsky et al., 1994; Parish et al., 2001) . HS is unique in its ability to sequester a multitude of proteins, ensuring that a wide variety of bioactive molecules, including heparin-binding proangiogenic factors, adhere to the cell surface and ECM (Iozzo, 1998; Bernfield et al., 1999; Gallagher, 2001) . Hence, apart from its direct involvement in basement membrane invasion by endothelial cells, heparanase elicits an indirect angiogenic response through release of HS-bound angiogenic growth factors (i.e., bFGF, VEGF) from the ECM and generation of HS fragments which can promote binding, dimerization and signaling of growth factor receptors (Elkin et al., 2001; Vlodavsky and Friedmann, 2001) . Heparanase may thus facilitate tumour cell invasion and neovascularization (Elkin et al., 2001; Goldshmidt et al., 2002) , both critical steps in tumour progression.
While expression of human heparanase in normal cells is restricted primarily to cytotrophoblasts, keratinocytes, platelets and activated cells of the immune system (Dempsey et al., 2000; Vlodavsky and Friedmann, 2001 ), the enzyme is preferentially and widely expressed in human carcinomas and certain leukemias (Friedmann et al., 2000; Gohji et al., 2001; Koliopanos et al., 2001; Bitan et al., 2002) . Given the potential tissue damage that could result from uncontrolled cleavage of HS, tight regulation and balance are essential. However, the mechanisms responsible for heparanase overexpression in cancer remain largely unknown. Mutational and functional analysis emphasize the importance of two ETS binding sites near the 5 0 portion of the human HPSE promoter in transactivation and upregulation of heparanase expression (Lu et al., 2003) . It was also suggested that the Sp1 and GABP transcription factors participate in a cooperative regulation of HPSE promoter activity (Jiang et al., 2002) .
The present study reports, for the first time, that promoter methylation is an epigenetic factor governing expression of the mammalian heparanase gene. Most cytosine bases followed by guanine are methylated in the mammalian genome. However, clusters of these generally sparse, under-represented CpG dinucleotides normally remain methylation-free (Bird, 1986; Cross and Bird, 1995) . Termed 'CpG islands' they are often associated with the 5 0 region of most housekeeping and many tissue-specific genes (Larsen et al., 1992) . Methylation of these areas correlates inversely with the transcription activity of the corresponding loci (Bird, 1986; Eden and Cedar, 1994; Cross and Bird, 1995; Miyakura et al., 2003) . Critical for development, cell differentiation, and inactivation of X chromosomes and imprinted genes, the normal methylation pattern is passed unaltered in cell generations (Ben-Porath and Cedar, 2000; Jones and Takai, 2001) . This is the best characterized example of the so-called epigenetic inheritance, i.e., differences in gene expression that are stably propagated in mitoses without alterations in nucleotide sequence (Jones and Takai, 2001) . As an antithesis to the normal pattern, the genome of a malignant cell is typically characterized by generalized hypomethylation alongside regional hypermethylation which often affects multiple tumour suppressor genes and apparently silences them (Melki et al., 1999; Toyota and Issa, 1999; Esteller et al., 2001) . Whilst epigenetic inactivation of tumour suppressor genes attracted much attention, activation of tumour progression factors by aberrant hypomethylation has been documented so far only for a small number of loci (Ehrlich, 2002) . Given the involvement of heparanase in cancer metastasis and angiogenesis, we sought to identify an epigenetic mechanism that may regulate expression of this mammalian gene. Our results indicate that the methylation status of the CpG island in the heparanase promoter plays an important role in silencing and activation of this tumour progressionrelated gene.
Results

Methylation status of the HPSE promoter CpG islands in human cancer cell lines
Analysis of the previously reported heparanase promoter region sequence (our data & GenBank entry AF461265) revealed a well-defined 483 bp CpG island (with 40 CpGs and GC content of 68%) immediately upstream to the translation initiation site (Figure 1 ). Methylation-specific PCR (MSP) screening of 22 cell lines representing various human cancers demonstrated existence of at least one methylated allele in 7 of them, as indicated by a PCR product obtained with primers specific to the originally methylated sequence (Figure 2a ). Heparanase activity expressed by representative cell lines is shown in Figure 2b . Briefly, incubation of sulfate labelled ECM with lysates of either Jurkat (T-cell lymphoma) or MeWo (melanoma) cells resulted in release of low molecular weight labelled material eluted in fractions 20-35 ( Figure 2b ) and characterized as degradation fragments of HS (i.e., susceptibility to nitrous acid deamination; resistance to chondroitinase ABC) (Vlodavsky et al., 1983) . In contrast, only a high molecular weight sulfate labelled material (nearly intact HSPGs eluted in fractions 1-10) and no HS degradation products were released upon incubation of the ECM with JAR (choriocarcinoma) cells (Figure 2b ), indicating absence of detectable heparanase activity.
Modification of genomic DNA with bisulfite converts all unmethylated cytosine residues into uracil and ultimately thymine (following PCR). Both forward and reverse primers used in these single step MSP experiments were specific for either the methylated or unmethylated state of the target CpGs. Given the presumed homogeneity of a cell line population, this approach is regarded as a reliable means to establish the methylation status of the primer binding sites. Nevertheless, we sought to confirm our findings with the bisulfite PCR method which does not involve selective amplification of alleles of a particular type and thus reduces risks of false positivity due to minor contamination, mispriming, or presence of a negligible fraction of a suitable template in the DNA samples. To that end, we designed primers devoid of CpG dinucleotides for unbiased amplification of bisulfite-modified DNA. The PCR products were subsequently treated with AciI, a restriction enzyme capable of recognizing multiple CpG sites that represent originally methylated cytosines followed by guanine bases in a CCGC/GCGG context. Thus, the amount of the original-sized product reflects the prevalence of unmethylated promoters, whereas the total luminosity of digestion bands represents the methylated alleles in samples with a mixed methylation pattern. This semi-quantitative analysis showed an excellent correlation with our MSP data. Table 1 summarizes the MSP and bisulfite PCR data combined with heparanase activity determined in cell lysates (Figure 3) . Altogether, considerable heparanase activity was detected in 15 of the 22 human cell lines studied. While the heparanase promoter was devoid of methylation in majority of the specimens, 5 cell lines demonstrated presence of both methylated and unmethylated alleles, and another two (JAR, Raji) appeared to harbour only methylated promoters. Remarkably, both of the latter cell lines also lacked heparanase activity. Moreover, none of the 22 cell lines displayed a combination of predominantly methylated promoter region and detectable heparanase activity (Table 1) . Hence, the observed distribution of methylation status vs. enzymatic activity suggested an important role for this epigenetic modification in silencing of the heparanase gene.
Promoter CpG island is fully methylated in a rat cell line lacking heparanase activity The significant homology of the human and rodent heparanase genes, as well as their apparently exclusive role in managing mammalian HSPGs, led us to perform a similar set of experiments with C-6 rat glioma cells previously shown to lack heparanase activity. Analysis of the GenBank entry No. AC106280 revealed a CpG island in the 5 0 region of the Hpse gene (with GC content of 450%, 28 CpGs and observed/expected CpG ratio of 0.71 in its part upstream to the first ATG). Remarkably, this similarity of the promoter's topology to its human counterpart was evident despite lack of homology at the sequence level. While the mRNA sequences of the two species share 80% of the 1487 nucleotides in the extensive overlap area (GenBank Accession Nos. AF165154 (human) and AF184967 (rat)), no significant similarity was found in the analyzed region of 640 nucleotides upstream to the translation initiation site. The locus was extensively methylated in C-6 glioma cells (Figures 4, 5a , 6a, 9a) whereas a methylation-free promoter was found in the tail DNA of the same strain of rats (Figures 6a, 8a, 9a) . Again, the association of the fully methylated pattern with absence of heparanase activity ( Figure 5b ) suggested a role for this heritable cis alteration in silencing of the corresponding heparanase gene.
Dose-and time-dependant restoration of heparanase expression following exposure to demethylating agents
To test the notion suggested by the apparent correlation of promoter methylation status and heparanase activity, we examined the functional impact of de novo demethylation induced in this locus by 5-azacytidine (5-azaC) or 5-aza-2 0 -deoxycytidine (5-aza-2dC). It is arguable that in cell lines with a mixed methylation pattern, the unmethylated alleles are inactivated by a genetic mutation or additional trans-acting factors. For that reason, in our subsequent experiments we focused on effects exerted by the DNA methyltransferase inhibitors on human (JAR) and rat (C-6 glioma) cells in which all alleles are extensively methylated and therefore are less likely to carry additional alterations. In these cell lines, we observed a prompt, significant response to demethylating agents, depending on both the dose ( Figure 7 ) and time ( Figure 5 ) of exposure. Already evident after 3 days of treatment ( Figure 5a ) and for at least 10 days following cessation of treatment (Figure 6a ), the hypomethylated status was invariably accompanied by a corresponding restoration of heparanase activity (Figures 5b, 6b, 7b) . This result indicates that the gain of heparanase activity following promoter demethylation with 5-aza-2dC is stable for at least several generations in culture.
Dense and extensive pattern of methylation in the heparanase promoter CpG island
Despite the consistency of the results obtained with the MSP and bisulfite PCR that cover multiple CpG sites, we also sought to probe all individual cytosines in the entire promoter region. Direct bisulfite sequencing of the CpG island amplicons was possible due to the apparent homogeneity within each of the cell lines. The results (exemplified in Figure 4 ) confirmed our previous findings and indicated essentially 'all or none' pattern of methylation in the analyzed region, with no preferentially affected patches both in original and drug-treated cells. Sequenced products also demonstrated complete bisulfite conversion of the antisense DNA strand amplified in the PCR reaction, as indicated by absence of guanine peaks unless preceded by a cytosine. Figure 3 Heparanase activity in human cell lines harbouring different HPSE promoter methylation patterns. Heparanase activity was determined in lysates of human cell lines that contain either unmethylated (J), methylated () or both kinds of HPSE promoters (m) (see Table 1 ), as described in the legend to Figure 2b Trichostatin a does not induce promoter hypomethylation and restoration of heparanase activity in heparanase nonexpressing cells Histone deacetylation in transcriptionally inactive regions is an epigenetic mechanism that complements cytosine methylation in regulation of gene expression (Razin, 1998) . The functional synergy is mediated by methyl-CpG binding proteins such as MeCP2, MBD1 and MBD2 that associate with histone deacetylases (HDACs) and recruit them to methylated DNA (Ng et al., 1999; Wade et al., 1999) . The subsequent histone modification leads to repressed chromatin structure. Trichostatin A (TSA) is a specific inhibitor of HDAC and is capable of upregulating transcription of numerous genes (Van Lint et al., 1996) . In our experiments, low to moderately cytotoxic range of TSA concentrations (10-50 nM for JAR cells and 50-400 nM for C-6 glioma) was applied for 48 h. No promoter hypomethylation or heparanase activity was noted following exposure of C-6 (Figure 8) or JAR (not shown) cells to TSA. The results indicate that transcriptional repression of the heparanase locus is determined primarily by DNA methylation and not by histone hypoacetylation. Similar priority of epigenetic mechanisms of inactivation has been demonstrated for several other loci (Cameron et al., 1999; Lynch et al., 2002) .
Chemically induced hypomethylation of the heparanase promoter markedly increases the levels of the corresponding transcript Next, C-6 glioma and JAR cells were pretreated with 5-aza-2dC and subjected to RT-PCR to confirm that the Lanes (left to right): untreated C-6 glioma cells; C-6 glioma cells (glioma) exposed to 0.2 mM of 5-aza-2dC for 3 (3d), 5 (5d) or 7 (7d) days; FX /HaeIII marker. (b) Heparanase activity. Untreated C-6 rat glioma cells ('); and C-6 glioma cells exposed to 0.2 mM 5-aza-2dC for 3 (&), 5 (), or 7 (W) days, were lysed and analyzed for heparanase activity, as described in Methods observed increase in heparanase activity is related to elevated levels of the corresponding mRNA, rather than to some post-translational trans effects of the demethylating treatment, such as heparanase protein stabilization, activation, etc. The results ( Figure 9 ) were in agreement with the notion that the methylation status of the heparanase promoter directly modulates its transcriptional activity. Changes in the amounts of the heparanase mRNA tightly correlated with heparanase promoter hypomethylation ( Figure 9 ) and with the accompanying increase in heparanase activity (Figures 5 and 6 ).
Heparanase protein is detected in the cytoplasm of heparanase non-expressing cells following treatment with demethylating agents C-6 glioma and JAR cells were subjected to immunostaining with anti-heparanase polyclonal antibodies (Ab3) before and after exposure to 5-aza-2dC (0.2 mM). or 5-azaC (1 mM) for 5 days. While the heparanase protein was not detected in control untreated cells, intense staining of the heparanase enzyme was noted in the cytoplasm of cells exposed to either 5-aza-2dC (Figure 10 ) or 5-azaC (not shown).
Lung colonization is increased following treatment with demethylating agents
Finally, we examined the effect of heparanase activation by 5-aza-2dC in an in vivo model of experimental metastasis. C-6 glioma cells were treated with 0.2 mm 5-aza-2dC for 3 days. The treated cells were injected (1 Â 10 5 cells per mouse) to the tail vein of male nude mice. Twenty days after initial injection, the mice were sacrificed, their lungs were excised and incubated in Bouin's solution for 3 h for better visualization of the metastatic colonies. A 5.8-fold increase in the number of lung colonies was observed with the 5-aza-2dC-treated cells (Figure 11 ). This increase was inhibited by treatment of the mice with laminaran sulfate (250 mg/ mouse, administered s.c. 20 min prior to the cells injection), a potent inhibitor of heparanase activity and experimental metastasis (not shown).
Discussion
Given the pivotal role of mammalian heparanase in normal embryonic development, tissue morphogenesis, Prolonged reactivation of heparanase expression following exposure to the demethylating agents. (a) Bisulfite PCR amplicons digested with AciI. Lanes (left to right): FX /HaeIII marker; rat tail DNA (RT); C-6 glioma cells (glioma) that were exposed to 0.2 mM 5-aza-2dC for 5 days and either harvested immediately (5d), or subcultured in absence of the drug for additional 3 (5d þ 3d), 7 (5d þ 7d) or 10 (5d þ 10d) days. (b) Heparanase activity. C-6 glioma cells were exposed to 0.2 mM 5-aza2dC for 5 days and either harvested immediately (), or grown for additional 3 (J), 7 (&), or 10 (W) days. Heparanase activity was determined in cell lysates, as described in Methods. Originally heparanase non-expressing glioma cells retain significant hypomethylation of the Hpse promoter and heparanase activity for at least 10 days following demethylating treatment vascularization and cancer progression, expression of this enzyme is expected to be tightly controlled. Aberrant upregulation of heparanase is associated with cancer metastasis and angiogenesis (Parish et al., 2001; Vlodavsky and Friedmann, 2001) . It is therefore imperative to elucidate the mechanisms responsible for the increase in heparanase activity during tumour progression.
Unlike the well characterized expression profile of the heparanase protein, little is known about regulation of the corresponding gene. Two recent reports describe mutational and functional analysis of the human HPSE promoter in three tumour cell lines (Jiang et al., 2002; Lu et al., 2003) . These studies identified a minimal basic promoter region of HPSE that spans 300-700 bp proximally to the ATG translation initiation site and contains binding sites for several groups of transcription factors. So far, the Sp1 and ETS families of transcription factors were studied and shown to participate and probably cooperate in the regulation of human heparanase expression. A greater influence was exerted by Sp1, GABP, ETS1 and ETS2 than by Sp3, PEA3 and ER81 (Jiang et al., 2002; Lu et al., 2003) . Apparent inconsistency in the definition of a minimal promoter in these reports and the variable expression levels of mammalian heparanase suggest that this non-redundant gene is governed by a complex multifactorial mechanism.
While the aforementioned studies focused on transactivating elements of HPSE regulation, we explored the potential cis-inhibitory regulation mediated by DNA methylation. Of interest, our initial analysis revealed well-defined CpG islands in the proximal part of both the human and rat heparanase promoters, a feature shared despite lack of sequence homology between the two species. We chose to study the 300 bp region adjacent to the first ATG, since it is characterized by high GC content and observed/expected CpG ratio. Moreover, this region was shown to possess the minimal basic promoter activity that is critical for regulation of the heparanase gene in humans (Jiang et al., 2002) . The inverse relationship between transcriptional activity of promoters and methylation status of the corresponding CpG islands is well established (Bird, 1986; Cross and Bird, 1995; Razin, 1998; Toyota and Issa, 1999; Miyakura et al., 2003) . In screening of transformed human cells we found that the differences in heparanase expression levels were accompanied by heterogeneity in promoter methylation status. Specimens with fully methylated, methylation-free and a mixture of methy- In vitro induced hypomethylation of mammalian heparanase promoter is closely followed by renewed expression of the corresponding transcript. (a) Bisulfite PCR amplicons digested with AciI. Lanes (left to right): FX /HaeIII marker rat tail DNA (RT); untreated C-6 rat glioma cells (glioma); C-6 glioma cells that were exposed to 0.2 mM of 5-aza-2dC for 3 (3d) or 5 (5d) days and harvested immediately or subcultured in absence of the drug for additional 3 (5d þ 3d), 5 (5d þ 5d), 7 (5d þ 7d) and 10 (5d þ 10d) days. (b) Levels of the heparanase transcript were assessed in the same samples as in (a) by semi-quantitative RT-PCR (normalized for the L-19 gene). Lanes (left to right): untreated C-6 rat glioma cells (glioma); C-6 glioma cells that were exposed to 0.2 mM of 5-aza-2dC for 3 (3d) or 5 (5d) days and harvested immediately or subcultured in absence of the drug for additional 3 (5d þ 3d), 5 (5d þ 5d), 7 (5d þ 7d) and 10 (5d þ 10d) days lated and unmethylated alleles were encountered. In agreement with the notion of epigenetic control of heparanase expression, all cell lines positive for the enzyme also harboured at least one unmethylated allele. Several instances of little or undetectable heparanase activity not accompanied by extensive promoter methylation can be attributed to inactivation by additional factors such as mutations, lack of necessary transcription factors, post-translational defects, etc. Transcription silencing by hypermethylation of CpG islands can accompany the establishment of immortal cell lines. However, active and methylation-free heparanase promoters found in most of the studied cell lines suggest that silencing of this locus does not confer significant growth advantage during in vitro culture and, wherever present, hypermethylation is less likely to pose an aquired artefact. It is also remarkable that in none of the 22 human cell lines a fully methylated pattern was accompanied by detectable expression of the enzyme. Altogether, these observations suggest an essential role for methylation in repression of HPSE promoter activity in the affected allele. To exclude as many additional factors as possible, we focused on the role of epigenetic regulation of heparanase in human and rodent cell lines harbouring only fully methylated heparanase alleles. In these cells (JAR human choriocarcinoma and C-6 rat glioma) the absence of heparanase activity is accompanied by a low metastatic potential in animal models. We employed demethylating agents (5-azacytidine and 5-aza-2 0 -deoxycytidine) known to inhibit DNA methylation machinery and capable of reactivating genes silenced by hypermethylation (Christman, 2002; Guo et al., 2002; Robert et al., 2003; Sato et al., 2003) . Our results clearly demonstrated a tight association between the druginduced hypomethylation and restoration of heparanase activity in both the human choriocarcinoma and rat glioma cells. This correlation was evident with regard to the dose and duration of the demethylating treatment. In contrast, modification of chromatin structure with Trichostatin A did not induce reactivation of the gene or promoter hypomethylation, indicating that epigenetic silencing of this locus is determined predominantly by cytosine methylation. The likelihood of a causative relationship was further reinforced by RT-PCR and immunostaining analyses that revealed a close association of demethylation with appearance of the previously undetectable heparanase transcript and protein, respectively. Remarkably, the observed upregulation of heparanase expression and activity was accompanied by augmented metastatic potential in vivo, as indicated by a marked increase in lung colonization by rat glioma cells that were first treated with 5-aza-2dC. Moreover, this potentiation was suppressed in mice treated with laminaran sulfate, previously shown to inhibit both heparanase activity and experimental metastasis (Miao et al., 1999) . It should also be noted that despite the differences between 5-aza and 5-aza-2dC in other aspects of their pharmacological activity (Santini et al., 2001) , both demethylating agents exerted similar effects on the heparanase promoter in the human and rodent cell lines. Thus, although trans activation by an unknown factor cannot be ruled out completely, the in vitro and in vivo data indicate an important role for cis effects of CpG methylation in transcriptional silencing of the heparanase promoter.
Our data with the human cell lines suggest that promoter methylation is probably sufficient for inactivation of the corresponding HPSE allele and that alternative mechanisms of silencing also exist. Indeed, the gene is likely to be strictly controlled at multiple levels because of its uniqueness and due to the importance of heparanase function in mammalian cells. In fact, expression of the enzyme in different cell types has already been shown to be regulated by a variety of transcription factors (e.g., NFkB, Sp1 and ETS families) (Andela et al., 2000; Jiang et al., 2002; Lu et al., 2003) , cytokines and hormones (e.g., estrogen, our unpublished results). Nevertheless, a general hypothetical model can plausibly incorporate the current evidence. It has been demonstrated that at least in some loci the long-term fate of a promoter may be determined by a combination of its initial methylation status and the level of transcription activity . While sporadic 'seeding' methylation diminishes with time in cells actively utilizing a promoter (Song et al., 2002) , low levels of expression enable a gradual increase in methylation density which is probably mediated by methylcytosine-binding proteins (MBDs) and associated complexes (Cameron et al., 1999) . In turn, changes in chromatin structure and steric interference reduce a promoter's transcriptional activity even further, and a vicious cycle is formed (Cameron et al., 1999; Jones and Wolffe, 1999) . Once the critical mass of cytosine Figure 11 Treatment with 5-aza-2dC increases lung colonization by C-6 glioma cells. C-6 glioma cells were cultured for 5 days with (bottom) or without (top) 0.2 mM 5-aza-2dC. The cells were dissociated with 0.02 mM EDTA in PBS and injected (1 Â 10 5 cells/mouse) into the tail vein of nude male mice. Twenty days following injection, the mice were sacrificed, their lungs were excised and incubated (3 h) in Bouin's solution for visualization of metastatic colonies. A 5.8-fold increase in the number of colonies on the lung surface was observed in mice inoculated with 5-aza-2dC-treated glioma cells compared to the untreated cells (455760 vs. 78727, respectively; n ¼ 6; Pp0.003) methylation accumulates, the epigenetic inactivation is stably inherited by the cell's progeny (Bird, 2002) . In this scenario, hypermethylation of the heparanase promoter would pose the endpoint of its silencing. More importantly, for a tumour cell in malignant progression it would be the primary impediment to overcome on the way to abnormal upregulation of this enzyme. The probability and timing of such an epigenetic mutation would depend, among other factors, on the degree of imbalance in the methylation machinery of cancer cells. Increased de novo demethylation of DNA could both initiate the process (Guo et al., 2002) and protect the hypomethylated state of an already reactived promoter (Cervoni and Szyf, 2001) . Consistent with the proposed model is our observation of at least temporary persistence of heparanase expression following cessation of treatment with a demethylating agent. Thus, ongoing transcription activity, heritable during several generations in culture, might delay reversal to the repressed hypermethylated state. Of additional interest, both families of transcription factors already known to modulate HPSE expression also relate to DNA methylation. GABP, ETS-1 and other ETS factors bind to target sequences in humans and rodents, depending on the methylation status of nearby cytosines (Yokomori et al., 1995 (Yokomori et al., , 1998 De Smet et al., 1996; Umezawa et al., 1997; Guo et al., 2002) , whereas Sp1 sites were shown to protect at least some CpG islands from spread of methylation present in adjacent repetitive sequences (Brandeis et al., 1994; Macleod et al., 1994; Siegfried et al., 1999) . Thus, it is reasonable to propose that the promoter activity of mammalian heparanase is determined by interplay of genetic and epigenetic factors.
Unlike the numerous publications describing epigenetic silencing of tumour suppressor genes, our results present one of the infrequently reported cases of a progression-related gene possibly activated by generalized hypomethylation, which is characteristic of the cancer genome. It is also noteworthy that recent studies implicate DNA methylation in the regulation of genes encoding urokinase-type plasminogen activator (Guo et al., 2002) and matrix metalloproteinases (Sato et al., 2003) . Analogous to heparanase, these enzymes are involved in degradation of the extracellular matrix. Expression of these proteinases in cancer cells is associated with promoter hypomethylation alongside increased invasiveness and metastasis (Guo et al., 2002; Sato et al., 2003) . Similarly, we have demonstrated a marked increase in both heparanase activity and lung colonization of cells that were pretreated with demethylating agents. In all likelihood, upregulation of several cell invasion-promoting genes contributes to the increase in metastatic potential that was induced in our in vivo experiments. Nevertheless, the diminution in lung colonization observed in mice treated with laminaran sulfate emphasizes the significance of heparanase in the metastatic process.
In order to substantiate the proposed inactivation of mammalian heparanase promoter by CpG island hypermethylation, we are currently studying this phenomenon in clinical samples of human tumours, in vitro and in animal models. The importance of elucidating the epigenetic regulation of heparanase expression stems from the enzyme's contribution to cancer metastasis and angiogenesis. Our results are also highly relevant with regard to the renewed interest in 5-aza and particularly 5-aza-2dC (decitabine) as anti-cancer drugs for tumours in which epigenetic silencing of critical regulatory genes has occurred (Christman, 2002) . Benefits of chemotherapy based on inhibitors of DNA cytosine methyltransferases should be weighed against the potentially increased risk of metastasis. Accordingly, lower dosages of demethylating drugs and their combination with inhibitors of histone deacetylases may preclude inadverent activation of heparanase and other progressionrelated genes.
Materials and methods
Cells
All human cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA). Cells were maintained in Dulbecco's Modified Eagle's medium (DMEM, 4.5 g glucose/liter) or RPMI medium supplemented with 1 mM glutamine, 50 mg/ml streptomycin, 50 U/ml penicillin, and 10% fetal calf serum (Biological Industries, Beit-Ha'Emek, Israel) at 371C in a 5% humidified incubator. Cultures of bovine corneal endothelial cells were established from steer eyes and maintained in DMEM (1 g glucose/liter) supplemented with 5% newborn calf serum, 10% FCS and 1 ng/ml bFGF, as described . Confluent cell cultures were dissociated with 0.05% trypsin and 0.02% EDTA in phosphate buffered saline and sub-cultured at a split ratio of 1:8 .
Treatment with demethylating agents and trichostatin A C-6 rat glioma (kindly provided by Dr. E. Keshet, The Hebrew University School of Medicine, Jerusalem, Israel) (Benjamin and Keshet, 1997) and JAR human choriocarcinoma cells (Rachmilewitz et al., 1995) were maintained in complete medium (DMEM, 10% FCS) for 12-18 h prior to exposure to the demethylating compounds 5-azacytidine (5-azaC) and 5-aza-2 0 -deoxycytidine (5-aza-2dC) (Sigma Israel, Rehovot). Subsequently, every 24 h the medium was replaced and a new aliquot of the drug was added. At the end of treatment, the medium was replaced once again and the cells were cultured under drug-free conditions for the specified periods of time. 5-azaC and 5-aza-2dC were dissolved in PBS and stored at À201C as 0.1 mm and 0.5 mm stock solutions, respectively. Trichostatin A (TSA) (Sigma Israel, Rehovot) stock solution (1 mg/ml in ethanol) was kept at À201C. The drugs were protected from light during storage and use.
Bisulfite modification of DNA Genomic DNA was extracted using standard organic extraction procedures and modified by sodium bisulfite (Clark et al., 1994) . For this purpose, 5 mg DNA were denatured at 951C for 15 min and subsequently chilled on ice for 2 min. Freshly prepared 2N NaOH was then added to a final concentration of 0.5 N in a total volume of 30 ml. After 15 min incubation at 371C, 450 ml of freshly prepared bisulfite reagent (see below) were added and the mixture was overlaid with mineral oil and allowed to incubate at 551C for 4 h. Following incubation, DNA was extracted using the Wizard DNA Clean-up kit (Promega, Madison,WI). Purified DNA was recovered in water and 2 N NaOH added to a final concentration of 0.3 N, followed by incubation for 15 min at 371C. Lambda DNA (1-1.5 mg, NEB, Beverly, MA) was added and the DNA precipitated in ethanol for overnight at À801C. DNA was subsequently recovered by centrifugation and dissolved in sterile water in preparation for PCR. The bisulfite reagent was prepared as follows: 1.9 g of sodium bisulfite (Sigma Israel, Rehovot) were slowly dissolved in sterile water on a gentle rocker. The total volume was 4 ml, containing 0.7 ml 2 N NaOH and 0.5 ml of a saturated solution of hydroquinone (Sigma) in water (Shteper et al., 2001) .
PCR mix and primers for bisulfite-modified DNA samples
Fifty or 100 ng of genomic DNA modified as above were included in 50 ml PCR reaction mixture containing buffer to 1X final concentration (10 mM Tris-HCl, pH 9, 50 mM KCl, 1.5 mM. MgCl 2 , 0.1% Triton X-100, 0.2 mg/ml BSA), primers (25 pmoles each), 1 ml of a standard dNTP solution (10 mmol/ L of each nucleotide) and 2 U of Taq polymerase. All PCR primers were designed to recognize the antisense strand of the DNA template after bisulfite conversion (Asimakopoulos et al., 1999) . 
Single-step methylation-specific PCR for the HPSE locus
Initially a single step methylation-specific PCR approach (Herman et al., 1996) was applied to the HPSE promoter. Primer pairs HFM-HRM and HFU-HRU were used for detection of methylated and unmethylated target sequences, respectively, following modification with bisulfite. The PCR cycles were 951C for 5 min, then 45 cycles of 941C for 40 s, 571C for 30 s, and 721C for 60 s. As a positive control, DNA from normal donor buffy-coat samples was in vitro methylated at CpG sites using CpG methylase (SssI methylase) (NEB, Beverly, MA) as per manufacturer's recommendations.
Bisulfite PCR
Semi-quantitative approach of bisulfite PCR (Velinov et al., 2000) was employed in order to confirm the status of unmethylated, methylated and hemimethylated samples. Primer pairs HF-HR and FR-RR were used for amplification of the heparanase proximal promoter regions in human and rat cell lines, respectively. The PCR cycles were 951C for 5 min, then 45 cycles of 951C for 60 s, 531C for 45 s, and 721C for 90 s. The PCR products were incubated for 3 h at 37 o C in a reaction volume of 30 ml with 20 U of the restriction enzyme AciI (NEB, Beverly, MA). In case of methylated initial template sequence, the endonuclease recognizes 2 CCGC/GCGG sites in HF-HR amplicons and 4 sites in FR-RR products. Digestion products were separated by 3% Nusieve agarose gel electophoresis and visualized by ethidium bromide staining.
Sequencing of bisulfite-modified DNA
To confirm the PCR results and assess methylation status of all cytosines in the examined region, CpG island amplicons were sequenced directly on an automated sequencer. Annealing temperatures used were 521C for primers FR, RR, HF, HR and 551C for primers HFM, HRM, HFU, HRU. Note that in case of bisulfite modification raw reading data should be analyzed since false positive peaks of the underrepresented dye emerge in the final output due to automatic normalization. Since the antisense strands of the HPSE and Hpse genes were studied, presence of guanine vs. adenine peaks indicates methylation status of cytosines in the original sequence.
Sequencing data analysis
Standard settings of the BLAST 2 sequences (version BLASTN 2.2. 4, standard parameters) (Tatusova and Madden, 1999) alignment tool were used for comparison of human and rat heparanase promoter or mRNA sequences.
RNA isolation, cDNA synthesis and RT PCR RNA was isolated with Tri Reagent (MRC, Cincinnati, OH) according to the manufacturer's instructions and was quantitated by ultraviolet absorption. After reverse transcription of 1 mg total RNA by oligo(dT) priming, the resulting single stranded cDNA was amplified using TaqDNA polymerase (Promega) and specific primers directed against human (H-hpa 2U:-5 0 -CCT CAT CCT CCT GGG TTC TC-3 0 ; H-hpa 4L: 5 0 -CCT CAG CAT CTT AGC CGT CTT T -3 0 ) and rat (R-hpa U: 5 0 -TTG CCT CTT GGT CAT ATT GGA-3 0 ; R-hpa L: 5 0 -GGT CAG GGG TGT CAT TCA TAA-3 0 ) heparanase. The PCR conditions were an initial denaturation at 951C for 2 min, denaturation at 961C for 15 s, annealing for 1 min at 581C, and extension for 1 min at 721C (33 cycles). Aliquots (10 ml) of the amplified cDNA were separated by 1.5% agarose gel electophoresis, visualized by ethidium bromide staining and compared to the expression level of a ribosomal gene L-19 (L-19U: 5 0 -atg cca act ctc gtc aac ag -3 0 ; L-19 L: 5 0 -GCG CTT TCG TGC TTC CTT-3 0 ) Goldshmidt et al., 2001 ).
Preparation of dishes coated with ECM
Bovine corneal endothelial cells were plated into 35-mm tissue culture dishes at an initial density of 2 Â 10 5 cells/ml and cultured as described above, except that 4% dextran T-40 was included in the growth medium . On day 12, the subendothelial ECM was exposed by dissolving the cell layer with PBS containing 0.5% Triton X-100 and 20 mM NH 4 OH, followed by four washes with PBS . The ECM remained intact, free of cellular debris and firmly attached to the entire area of the tissue culture dish. To produce sulfate labeled ECM, Na 2 35 SO 4 (25 mCi/ml) (Amersham, Buckinghamshire, UK) was added on days 2 and 5 after seeding and the cultures were incubated with the label without medium change and processed as described . Nearly 80% of the ECM radioactivity was incorporated into HSPGs.
Heparanase activity
Cells (3 Â 10 6 cells/ml) were lysed by 3 cycles of freezing and thawing in phosphate citrate buffer, pH 6.0, and incubated (16 h, 371C, pH 6.0) with 35 S-labeled ECM. The incubation medium was centrifuged and the supernatant containing sulfate labeled degradation fragments was analyzed by gel filtration on a Sepharose CL-6B column (0.9 Â 30 cm) (Vlodavsky et al., 1983; Vlodavsky et al., 1999). Fractions (0.2 ml) were eluted with PBS and their radioactivity counted in a b-scintillation counter. Degradation fragments of HS side chains were eluted from Sepharose 6B at 0.5 o K av o 0.8 (peak II, fractions 20-30). Nearly intact HSPGs were eluted just after the V 0 (K av o 0.2, peak I) (Vlodavsky et al., 1983; Vlodavsky et al., 1999; Goldshmidt et al., 2001) . Each experiment was performed at least 3 times and the variation in elution positions (Kav values) did not exceed 7 15%.
Indirect immunofluorescence
Cultured rat C-6 glioma and human JAR choriocarcinoma were stained by indirect immunofluorescence as previously described (Goldshmidt et al., 2001; Goldshmidt et al., 2002) . Briefly, cells were fixed with either acetone (À201C, 5 min), or 4% formaldehyde in PBS for 20 min, and permeabilized with 0.5% Triton X-100 in PBS for 5 min. The cells were then incubated with polyclonal anti-heparanase antibodies (diluted 1 : 200) followed by staining with secondary Cy3-conjugated goat anti-rabbit antibodies, diluted 1 : 200. The anti-heparanase antibodies are directed against a synthetic peptide representing the N-terminus of the human enzyme (Fairbanks et al., 1999) . These antibodies recognize both the human and rat heparanase enzymes.
Experimental metastasis
Nude mice (n ¼ 6 mice per group) received a single i.p. injection of 0.2 ml PBS (control) or 0.2 ml PBS containing 300 g of laminaran sulfate, 20 min prior to i.v. (tail vein) inoculation of rat C-6 glioma cells (1 Â 10 5 cells/mouse) that were either incubated with 5-aza-2dC (5 days; 0.2 mM) or left untreated. The animals were sacrificed 20 days later; following fixation, their lungs surface was examined for the number of glioma cell colonies (Vlodavsky et al., 1994) . The data were analyzed for significance by using two tailed Student's t-test. Results are expressed as mean7SD.
